Drug Resistance Mutations in HIV Type 1 Isolates from Patients Failing Antiretroviral Therapy in Morocco

Annaz, Hicham El; Recordon-Pinson, Patrícia; Tagajdid, Reda; Doblali, Toufik; Belefquih, Bouchra; Oumakhir, S.; Sedrati, O.; Mrani, Saâd; Fleury, Hervé

doi:10.1089/aid.2011.0278

Cited by 8 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRF06_cpx is the second most prevalent strain of HIV‐1 isolated in our study and was found at a similar frequency in Niger [Mamadou et al, ]. In contrast, only one subtype B strain was identified in Mauritania, although it is still the major variant circulating in the northern neighboring countries such as Algeria, Morocco and Tunisia [Mumtaz et al, ; El Annaz et al, ]. A rate of 15.4% of unique recombinant forms were also found with a similar rate to that reported in Senegal [Thiam et al, ], but lower than the one reported in Mali [Maiga et al, ].…”

Section: Discussionsupporting

confidence: 86%

Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania

Fall-Malick

Tchiakpé

Soufiane

et al. 2013

Journal of Medical Virology

View full text Add to dashboard Cite

The aim of this cross-sectional study was to evaluate the drug resistance mutationprofile observed in patients receiving antiretroviral therapy with virological failure and to document the HIV-1 genetic diversity in Mauritania. Eighty-six subjects were included and 65 samples were amplified successfully and sequenced. HIV-1 genotyping was performed using the Agence Nationale de Recherche sur le SIDA AC11 resistance procedure. The median treatment duration was 32 months (range: 6-88) and the median viral load, 5 log10 copies/ml (range: 3.13-7). Fifty-nine patients (90.8%) were on first line regimens including 32.0% (19/59) on triomune fixed-dose and six on second-line therapy with NonNucleoside Reverse Transcriptase plus a protease inhibitor. Forty-seven patients (72.3%) had at least one drug resistance mutation including 73.0% (43/59) on first-line therapy. For the second-line, one out of six patients presented resistance mutations and only one presented PI DRM. Overall, the most common DRMs detected were M184V/I (n = 32; 49.2%), K103N (n = 28; 43%), and Y181C (n = 13; 20%). Thymidine Analog Mutations (TAMs) were found in 26.0% (n = 17) of strains and the most common was T215Y (n = 11, 16.9%). Phylogenetic analysis revealed 17 HIV-1 variants with the predominance of CRF02_AG (n = 42; 64.6%). A high rate of DRM was found in this study and shows the potential need for a structured virological surveillance including viral load quantification and genotyping. Further studies may also be needed in regards to the great variability of HIV-1 strains in Mauritania.

show abstract

Section: Discussionsupporting

confidence: 86%

Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania

Fall-Malick

Tchiakpé

Soufiane

et al. 2013

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…It was selected by lamivudine (3TC), emtricitabine (FTC) or ABC use and 3TC resistance with high level 24. This result was more highly observed than other mutations similar to the findings of other studies: Winand et al (M184V: 44.0%, n=3,554)25 and El Annaz et al (M184V: 44.0%, n=45) 26. This finding can be explained by the M184V mutation in line with lamivudine (3TC) resistance 27.…”

Section: Discussionsupporting

confidence: 90%

<p>Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam</p>

Tien

Pho

Hong

et al. 2019

IDR

View full text Add to dashboard Cite

Objectives: To study the prevalence of drug resistance and genotype testing for HIV drug resistance on HIV/AIDS patients with first-line antiretroviral treatment failure at Dong Da Hospital, Hanoi, Vietnam. Patients and methods: Forty-seven patients in Dong Da Hospital, Hanoi, with confirmation of first-line antiretroviral therapy (ART) failure were enrolled in this study from June 2006 to December 2016. Both the protease and reverse transcriptase genes were amplified and sequenced using Trugene ® HIV-1 Genotyping Kit and OpenGene ® DNA system at the biomolecular laboratory of the National Institute of Hygiene and Epidemiology, Vietnam. The Stanford HIV database algorithm was used for interpretation of resistance data and genotyping. Results: Drug resistance mutations were 90.7% in patients with first-line treatment failure. Amongst patients with drug resistance mutation, 97.7% resisted to non-nucleoside reverse transcriptase inhibitors (NNRTIs), followed by nucleoside reverse transcriptase inhibitors (NRTIs, 95.3%) and protease inhibitors (PIs, 11.6%). Amongst the genetic mutations resistant to NNRTIs, G190S mutation was the highest (51.2%), K101HQ mutation was 39.5% and Y181I mutation was 34.9%. In genetic mutations to NRTIs, M184V mutation was 88.4%. In thymidine analogue mutations, K70R mutation was the most common (37.2%), followed by D67N, T215F and T69N mutations (27.9%, 27.9% and 25.6%, respectively). In genetic mutations in PIs, M36I and K20R mutations made up 9.3%. In NNRTIs, the prevalence of nevirapine resistance was 55.8%, and that of efavirenz resistance was 4.7%. In NRTIs, the ratio of lamivudine resistance was 93.0%, and that of zidovudine resistance was 9.3%. No lopinavir/ritonavir resistance was recorded. Conclusions: Drug resistance mutations in patients with first-line ART failure had a high prevalence of NNRTI and NRTI resistance but still susceptible to PIs.

show abstract

“…According to previous Moroccan studies, the prevalence of resistance to NRTIs, NNRTIs and PIs are continuously increasing among drug-naïve and treatment experienced patients [ 2 – 4 ], thus, developing new drugs for AIDS treatment would be needed.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco

Alaoui

Touil

et al. 2018

BMC Res Notes

Self Cite

View full text Add to dashboard Cite

ObjectiveThe integrase strand-transfer inhibitors (INSTIs) are an important class in the arsenal of antiretroviral drugs designed to block the integration of HIV-1 cDNA into the host DNA through the inhibition of DNA strand transfer. In this study for the first time in Morocco, the complete HIV-1 integrase gene was analysed from newly diagnosed patients to evaluate the prevalence of natural polymorphisms and INSTIs resistance-associated mutations in the integrase gene.ResultsThe 864pb IN coding region was successfully sequenced from plasma sample for 77 among 80 antiretroviral naïve patients. The sequences were interpreted for drug resistance according to the Stanford algorithm. Sixty samples were HIV-1 subtype B (78%), fourteen CRF02_AG (18%), two subtype C and one subtype A. Overall 81 of 288 (28%) amino acid IN positions presented at least one polymorphism each. We found 18 (36.73%), 42 (25.76%) and 21 (27.27%) of polymorphic residues assigned to the N-Terminal Domain, Catalytic Core Domaine and the C-Terminal Domain positions respectively. Primary INSTIs resistance mutation were absent, however secondary mutations L74IM, T97A were detected in four samples (5.2%). These results demonstrate that untreated HIV-1 infected Moroccans will be susceptible to INSTIs.Electronic supplementary materialThe online version of this article (10.1186/s13104-018-3492-5) contains supplementary material, which is available to authorized users.

show abstract

Drug Resistance Mutations in HIV Type 1 Isolates from Patients Failing Antiretroviral Therapy in Morocco

Cited by 8 publications

References 29 publications

Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania

Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania

<p>Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam</p>

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco

Contact Info

Product

Resources

About